BCG IN TREATMENT OF NEWLY DIAGNOSED TYPE 1 DIABETIC PATIENTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KASHEF S.; KARAMIZADEH Z.; KASHEF MAHSAN

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: IRANIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM) Year:2002 | Volume:4 | Issue:3 (SN 15) Page(s): 179-183

Download Full-Text

Persian Verion

View:

1,792

Download:

Cites:

Information Journal Paper

Title

BCG IN TREATMENT OF NEWLY DIAGNOSED TYPE 1 DIABETIC PATIENTS

Author(s)

KASHEF S. | KARAMIZADEH Z. | KASHEF MAHSAN | Issue Writer Certificate

Keywords

TYPE 1 DIABETESQ3

AUTOIMMUNITYQ3

BCGQ4

TREATMENTQ2

INSULINQ3

Abstract

Introduction: TYPE 1 DIABETES is believed to be an autoimmune disease. Pancreatic islet cell destruction occurs by infiltration of T lymphocytes. BCG vaccine modulates the development of TYPE 1 DIABETES in animal models. Based upon the studies in animals and man a clinical trial using a single dose of BCG vaccine was carried out in newly diagnosed type 1 diabetic patients. Material and methods: Ten newly diagnosed type 1 diabetic patients 4-14 years of age, were enrolled in this study. All patients had been vaccinated with BCG at birth. PPD positive patients and those with other autoimmune diseases were excluded from this study. Single dose of BCG (0.1 ml of 1 mg/ml) was administered intracutaneously to all patients. Ten newly diagnosed type 1 diabetic patients matched for age and sex were also followed as the control group. All patients were followed with fasting blood sugar, HbA1c and the needed INSULIN per kg of body weight for nine months. Results: There was no significant difference in fasting sugar, INSULIN dose & HbA1c levels at any time between the BCG-vaccinated and control groups. Conclusion: Our study does not support the effect of BCG therapy in this group of diabetic patients.

Cites

No record.

References

No record.

Cite

APA: Copy

KASHEF, S., KARAMIZADEH, Z., & KASHEF, MAHSAN. (2002). BCG IN TREATMENT OF NEWLY DIAGNOSED TYPE 1 DIABETIC PATIENTS. IRANIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM), 4(3 (SN 15)), 179-183. SID. https://sid.ir/paper/27686/en

Vancouver: Copy

KASHEF S., KARAMIZADEH Z., KASHEF MAHSAN. BCG IN TREATMENT OF NEWLY DIAGNOSED TYPE 1 DIABETIC PATIENTS. IRANIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM)[Internet]. 2002;4(3 (SN 15)):179-183. Available from: https://sid.ir/paper/27686/en

IEEE: Copy

S. KASHEF, Z. KARAMIZADEH, and MAHSAN KASHEF, “BCG IN TREATMENT OF NEWLY DIAGNOSED TYPE 1 DIABETIC PATIENTS,” IRANIAN JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM), vol. 4, no. 3 (SN 15), pp. 179–183, 2002, [Online]. Available: https://sid.ir/paper/27686/en

Related Journal Papers